CADTH Canadian Drug Expert Committee recommendation: Levodopa/carbidopa intestinal gel (Duodopa -- Abbvie Corporation) indication : Parkinson's disease

The CADTH Canadian Drug Expert Committee recommends that levodopa/carbidopa intestinal gel (LCIG) be reimbursed for the treatment of patients with advanced levodopa-responsive Parkinson disease (PD) who do not have satisfactory control of motor fluctuations and hyper-/dyskinesia despite optimized tr...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, 2018 Aug
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02043nam a2200361 u 4500
001 EB001872268
003 EBX01000000000000001035639
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190824 r ||| eng
245 0 0 |a CADTH Canadian Drug Expert Committee recommendation: Levodopa/carbidopa intestinal gel (Duodopa -- Abbvie Corporation)  |h Elektronische Ressource  |b indication : Parkinson's disease 
246 3 1 |a Drug reimbursement recommendation Levodopa/carbidopa intestinal gel (Duodopa) 
246 3 1 |a Levodopa/carbidopa intestinal gel (Duodopa -- Abbvie Corporation) 
250 |a Version 1.0 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2018, 2018 Aug 
300 |a 1 PDF file (9 pages) 
653 |a Insurance, Health, Reimbursement 
653 |a Parkinson Disease / drug therapy 
653 |a Canada 
653 |a Carbidopa / therapeutic use 
653 |a Cost-Benefit Analysis 
653 |a Antiparkinson Agents / economics 
653 |a Levodopa / therapeutic use 
710 2 |a CADTH Canadian Drug Expert Committee 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
500 |a "Final" 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK539327  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
082 0 |a 330 
520 |a The CADTH Canadian Drug Expert Committee recommends that levodopa/carbidopa intestinal gel (LCIG) be reimbursed for the treatment of patients with advanced levodopa-responsive Parkinson disease (PD) who do not have satisfactory control of motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of PD medicinal products, and for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomyjejunostomy tube required for administration